Cutera, Inc. Appoints Taylor Harris as Chief Executive Officer
27 Julho 2023 - 10:00AM
Business Wire
Follows Comprehensive Search Process; Brings
Over 20 Years of Healthcare Industry Experience and Operational
Expertise
CUTERA, INC. (“Cutera” or the “Company”) (Nasdaq: CUTR), a
leading provider of aesthetic and dermatology solutions, today
announced that Taylor Harris has been appointed Chief Executive
Officer, effective August 7, 2023. Mr. Harris will succeed Sheila
Hopkins, who has been serving as Interim Chief Executive Officer
since April 2023. Mr. Harris and Ms. Hopkins will both continue
serving as members of Cutera’s Board of Directors.
Mr. Harris joined Cutera’s Board in June 2023. He is a proven
executive and brings over 20 years of operational expertise as well
as healthcare and life science industry experience to the Company.
He most recently served as Senior Vice President and Chief
Financial Officer of MyoKardia, a clinical-stage biopharmaceutical
company, until the company’s sale to Bristol Myers Squibb in 2020.
Previously, Mr. Harris served as Senior Vice President and Chief
Financial Officer of ZELTIQ Aesthetics, where he was responsible
for overseeing global finance, accounting, tax, treasury, investor
relations, and information technology functions, as well as the
company’s commercial operations, including customer service,
product support, and inside sales. Mr. Harris also served as Chief
Financial Officer at Thoratec Corporation, and prior to that he
worked at JP Morgan Chase & Co. for over a decade with a focus
on the medical device industry.
Kevin Cameron, Chair of the Cutera Board of Directors, said,
“Taylor’s appointment follows a comprehensive search process to
identify the right leader to execute on Cutera’s strategy and
capitalize on additional growth opportunities across the Company’s
global footprint. Taylor has a longstanding track record of
successfully leading and growing companies in the healthcare
industry, and we are confident he is the right leader to help
Cutera accelerate our momentum, sharpen our execution and create
value for our stockholders.”
Mr. Harris said, “I am honored to take on the role of Chief
Executive Officer during such an important time for the Company.
For a number of years, I’ve been impressed with Cutera’s commitment
to customers, quality, and innovation. Over the past month serving
on Cutera’s Board of Directors, I have seen firsthand the
tremendous work the team is doing, and I believe that Cutera’s core
business, the exciting AviClear opportunity, and the company’s new
product engine provide a strong foundation for long-term success. I
look forward to working alongside the talented and committed team
at Cutera to drive growth and profitability, expand our innovative
portfolio, and deliver amazing results for our customers and their
patients.”
Mr. Cameron continued, “On behalf of the Board, I’d like to
thank Sheila for her leadership and steady hand during a critical
period in the Company’s history. Over the last few months, she has
worked hard to keep the organization focused on delivering for our
customers and advancing key strategic priorities. We would also
like to thank all Cutera employees for their patience while the
Board conducted its CEO search process.”
Ms. Hopkins, Interim CEO, said, “It has been a privilege to
serve as Cutera’s Interim CEO. In the time I’ve been in this role,
I’ve gained even deeper insight into Cutera’s business, people and
strategy. I’m more confident than ever that Cutera is
well-positioned for growth under Taylor’s leadership, and I look
forward to applying my learnings as Interim CEO upon returning to
my position as an independent director on the Board.”
About Taylor Harris
Mr. Harris served as the Chief Financial Officer for MyoKardia,
from 2018 until that company's acquisition by Bristol Myers Squibb
in 2020. Prior to that, Mr. Harris served as Senior Vice President
and Chief Financial Officer of ZELTIQ Aesthetics, until that
company’s acquisition by Allergan plc. He also served as Vice
President and Chief Financial Officer at Thoratec Corporation,
which was eventually acquired by St. Jude Medical, Inc and worked
at JPMorgan Chase & Co. for over a decade in several
capacities, including as a Vice President in the firm’s Healthcare
Investment Banking and Equity Research departments. Mr. Harris
holds a B.A. from the University of North Carolina at Chapel Hill,
where he studied as a Morehead-Cain scholar.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of
aesthetic and dermatology solutions for practitioners worldwide.
Since 1998, Cutera has been developing innovative, easy-to-use
products that harness the power of science and nature to enable
medical practitioners to offer safe and effective treatments to
their patients. For more information, call +1-415-657-5500 or
1-888-4CUTERA or visit www.cutera.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230726862833/en/
Greg Barker VP, Corporate FP&A 415-657-5500
IR@cutera.com
Eric Brielmann / Rachel Goldman Joele Frank, Wilkinson Brimmer
Katcher 212-355-4449
Cutera (NASDAQ:CUTR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cutera (NASDAQ:CUTR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024